Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2017: Following the practice changing results from STAMPEDE

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 05.06.17
Views: 3072

Dr Neal Shore and Prof Nicholas James

Dr Neal Shore (Carolina Urologic Research Center, Myrtle Beach, South Carolina, USA) and Professor Nicholas James (Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK) look at the latest prostate cancer data presented at ASCO 2017.

Dr Shore asks Prof James to signpost what future clinical trial development changes will occur -  Prof James indicates that future new arms to STAMPEDE will focus on adding metformin, transdermal oestrogen patches, PARP inhibition and increased utility of circulating cell-free DNA. The experts also touch on the importance of addressing health economic aspects of additive therapies - the reduction of skeletal events being one important key factor to off-set additive costs. 

Read the news story for more. 

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutical (A Johnson & Johnson Company).

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation